Ataluren treatment of patients with nonsense mutation dystrophinopathy

FOR THE PTC124-GD-007-DMD STUDY GROUP

Research output: Contribution to journalArticlepeer-review

229 Scopus citations

Abstract

Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders. Methods: Randomized, double-blind, placebo-controlled study; males ≥5 years with nm-dystrophinopathy received study drug orally 3 times daily, ataluren 10, 10, 20 mg/kg (N=57); ataluren 20, 20, 40 mg/kg (N=60); or placebo (N=57) for 48 weeks. The primary endpoint was change in 6-Minute Walk Distance (6MWD) at Week 48. Results: Ataluren was generally well tolerated. The primary endpoint favored ataluren 10, 10, 20 mg/kg versus placebo; the week 48 6MWD Δ=31.3 meters, post hoc P=0.056. Secondary endpoints (timed function tests) showed meaningful differences between ataluren 10, 10, 20 mg/kg, and placebo. Conclusions: As the first investigational new drug targeting the underlying cause of nm-dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.

Original languageEnglish
Pages (from-to)477-487
Number of pages11
JournalMuscle and Nerve
Volume50
Issue number4
DOIs
StatePublished - Oct 1 2014

Keywords

  • Duchenne muscular dystrophy
  • Genetic
  • Nonsense mutation
  • Orphan
  • Pediatric

Fingerprint Dive into the research topics of 'Ataluren treatment of patients with nonsense mutation dystrophinopathy'. Together they form a unique fingerprint.

Cite this